Absci Company

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.
Technology: Anti-infective Drugs
Industry: Early Drug Development
Headquarters: Vancouver, Washington, United States
Founded Date: 2011-01-01
Employees Number: 101-250
Funding Status: IPO
Investors Number: 23
Total Funding: 237859989
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-03-23
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership